Skip to content
Decision-ready map
• Write sex-aware requirements: Hb ranges, skin optics, perfusion states
• Collect reference standards and stratify metrics by sex + mediators
• Report tail-risk near thresholds (false reassurance/false alarms)
• Design quality/uncertainty gating when coupling is poor
• Revalidate after hardware/firmware/ML updates (change control)
(1) What it is
For optical health-tech products, sex-based biological differences are a systems requirement, not an ethics add-on. Your PPG/SpO₂, spectroscopy, or NIRS pipeline estimates physiology by inverting absorption/scattering and hemodynamic assumptions. Sex-linked differences in hemoglobin distributions (absorption), skin optical properties (scattering/path length), and microvascular perfusion (SNR and dynamics) can shift feature distributions and create subgroup-specific error tails. ‘What to validate’ means: demonstrate that performance and safety metrics near your claim thresholds hold across sexes and relevant life stages, and that you can maintain that parity after product updates.
(2) Who it helps
This brief is for founders and product leads defining intended use, claims, validation endpoints, dataset strategy, and postmarket monitoring for wearables (PPG/SpO₂), point spectroscopy (DRS/fluorescence/Raman), and NIRS/tissue oximetry.
(3) What evidence exists
Empirical evidence supports sex-linked signal differences. PPG waveform timing/morphology features differ by sex, which can propagate into HRV, vascular indices, or SpO₂-adjacent models (Dehghanojamahalleh & Kaya 2019). Large-cohort in vivo DRS inversions report sex-associated absorption and reduced scattering coefficients, indicating that forward-model parameters vary across the market you will serve (Jonasson et al. 2023). Combined DRS/LDF microcirculation studies show lower RBC tissue fraction and perfusion in females, which affects amplitude, quality flags, and calibration stability (Samils et al. 2023). Time-resolved NIRS shows sex differences in baseline oxygenated hemoglobin concentration, a direct warning against universal baseline thresholds (Asahara & Matsukawa 2023). Skin autofluorescence differs by sex for some bands, suggesting endogenous fluorophore baselines are sex-modulated (Morvová et al. 2018). Raman spectroscopy has been demonstrated as a non-targeted biomarker quantification approach in serum, underscoring that spectral signatures embed physiology that can vary by population; therefore, sex-stratified validation is prudent (Staritzbichler et al. 2021).
(4) Translation barriers
Common translation barriers include: (i) claim–evidence mismatch (e.g., clinical decision support claims without threshold-tail validation), (ii) underpowered subgroup sampling, (iii) recording sex without mediators (Hb, pregnancy) so differences cannot be debugged, (iv) device and algorithm drift after updates, and (v) reporting pooled mean error rather than worst-group or tail-risk metrics. Wearables add coupling confounds: fit/contact pressure and wear patterns can differ and must be separated from physiology.
(5) Equity/safety checks
Treat sex as one stratification variable and avoid conflating sex with gender identity. Where intended use includes pregnancy or anemia-prone settings, include them in evidence plans or clearly label limitations. Implement safety by design: signal-quality indices, uncertainty estimation, conservative output suppression when coupling is poor, and human-in-the-loop pathways for ambiguous cases. Align processes with FDA expectations for sex-specific data and document change control to protect subgroup performance.
(6) Decision questions
• What is the intended use and decision impact, and which failure mode is unacceptable (false reassurance vs false alarm)?
• Does the dataset span sexes and relevant life stages (pregnancy/menopause) and Hb ranges?
• Are metrics worst-group and tail-risk near thresholds—not only average error?
• How will you separate physiology from coupling (fit/contact pressure, site choice) in studies?
• What triggers revalidation after optics/BOM, firmware, or ML updates, and how will field drift be monitored?
(7) Practical next steps
1) Write sex-linked failure modes into product requirements (Hb, scattering/path length, perfusion states, life stage).
2) Design validation with reference standards (SaO₂/co-oximetry for SpO₂, lab Hb, clinical endpoints) and pre-specify sex-disaggregated analyses.
3) Report distributions and tail-risk metrics near thresholds; publish tested conditions and limitations.
4) Implement uncertainty/quality gating and conservative fallbacks.
5) Establish change control: revalidate after updates and monitor subgroup drift postmarket.
(8) References
Dehghanojamahalleh S, Kaya M. Sex-Related Differences in Photoplethysmography Signals Measured From Finger and Toe. IEEE J Transl Eng Health Med. 2019;7:1900607.
https://doi.org/10.1109/JTEHM.2019.2938506
Charlton PH, Pilt K, Kyriacou PA. Establishing best practices in photoplethysmography signal acquisition and processing. Physiol Meas. 2022;43(5):050301.
https://doi.org/10.1088/1361-6579/ac6cc4
Jonasson H, Fredriksson I, Bergstrand S, et al. Absorption and reduced scattering coefficients in epidermis and dermis from a Swedish cohort study. J Biomed Opt. 2023;28(11):115001.
https://doi.org/10.1117/1.JBO.28.11.115001
Samils L, Henricson J, Strömberg T, Fredriksson I, Iredahl F. Workload and sex effects in comprehensive assessment of cutaneous microcirculation. Microvasc Res. 2023;148:104547.
https://doi.org/10.1016/j.mvr.2023.104547
Asahara R, Matsukawa K. Prefrontal oxygenation is quantified with time-resolved NIRS: effect of sex on baseline oxygenation and response during exercise. Am J Physiol Regul Integr Comp Physiol. 2023;325:R31–R44.
https://doi.org/10.1152/ajpregu.00048.2023
Morvová M Jr, Jeczko P, Šikurová L. Gender differences in the fluorescence of human skin in young healthy adults. Skin Res Technol. 2018;24(4):599–605.
https://doi.org/10.1111/srt.12471
Hung C-H, Chou T-C, Hsu C-K, Tseng S-H. Broadband absorption and reduced scattering spectra of in-vivo skin using δ-P1 approximation. Biomed Opt Express. 2015;6(2):443–456.
https://doi.org/10.1364/BOE.6.000443
Staritzbichler R, Hunold P, Estrela-Lopis I, et al. Raman spectroscopy on blood serum samples of patients with end-stage liver disease. PLoS One. 2021;16(9):e0256045.
https://doi.org/10.1371/journal.pone.0256045
WHO. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. 2024.
https://www.who.int/publications/i/item/9789240088542
NIH Office of Research on Women’s Health. Sex as a Biological Variable (SABV).
https://orwh.od.nih.gov/sex-as-biological-variable
FDA. Evaluation of Sex-Specific Data in Medical Device Clinical Studies (final guidance). March 2025.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-sex-specific-data-medical-device-clinical-studies-guidance-industry-and-food-and-drug